Expert Perspective: FDA CRDAC Vote on Patisiran for ATTR-CM, with Ahmad Masri, MD, MS
September 16, 2023
Ahmad Masri, M.D., discusses the results of a Phase 3 clinical trial evaluating the drug patisiran as a potential treatment for the rare heart condition transthyretin-mediated amyloidosis.